Research programme: immunotherapeutics - Nextera AS

Drug Profile

Research programme: immunotherapeutics - Nextera AS

Latest Information Update: 27 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nextera
  • Class
  • Mechanism of Action HLA antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Crohn's disease; Haematological malignancies

Most Recent Events

  • 21 Sep 2015 Nextera AS and Janssen Biotech agree to conduct verification studies using Nextera's technology in Norway for Rheumatoid Arthritis
  • 21 Sep 2015 Early research in Crohn's disease in Norway (unspecified route)
  • 21 Sep 2015 Early research in Haematological malignancies in Norway (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top